دورية أكاديمية
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers.
| العنوان: | Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. |
|---|---|
| المؤلفون: | Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Clinical Oncology, Faculty of Medicine, Menoufia University. Shebin Al-Kom, Egypt., Huang HJ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Call SG; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Karp DD; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Fu S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Subbiah V; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Pant S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Dustin DJ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Rodon J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Janku F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX. |
| المصدر: | JCO precision oncology [JCO Precis Oncol] 2022 Jul; Vol. 6, pp. e2100512. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Alexandria, VA : American Society of Clinical Oncology, [2017]- |
| مواضيع طبية MeSH: | Circulating Tumor DNA*/genetics , Neoplasms*/genetics, Biomarkers, Tumor/genetics ; Humans ; Liquid Biopsy ; Treatment Outcome |
| مستخلص: | Purpose: The response to cancer therapies is typically assessed with radiologic imaging 6-10 weeks after treatment initiation. Circulating tumor DNA (ctDNA), however, has a short half-life, and dynamic changes in ctDNA quantity may allow for earlier assessment of the therapeutic response. Methods: Patients with advanced solid tumors referred to the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center were invited to participate in a liquid biopsy protocol for which serial blood samples were collected before, during, and after systemic therapy. We isolated ctDNA from serially collected plasma samples at baseline, mid-treatment, and first restaging. Genomically informed droplet digital polymerase chain reaction (ddPCR) was performed, and ctDNA quantities were reported as aggregate variant allele frequencies for all detected molecular aberrations. Results: We included 204 patients receiving 260 systemic therapies. The ctDNA detection rate was higher in progressors (patients with progressive disease) compared with nonprogressors (patients with stable disease, partial responses, or complete responses) at all time points ( P < .009). Moreover, ctDNA detection was associated with a shorter median time-to-treatment failure ( P ≤ .001). Positive delta and slope values for changes in ctDNA quantity were more frequent in progressors ( P ≤ .03 and P < .001, respectively) and were associated with a shorter median time-to-treatment failure ( P ≤ .014 and P < .001, respectively). Increasing ctDNA quantity was predictive of clinical and/or radiologic progressive disease in 73% of patients (median lead time, 23 days). Conclusion: Detection of ctDNA and early dynamic changes in its quantity can predict the clinical outcomes of systemic therapies in patients with advanced solid tumors. |
| References: | Ann Oncol. 2019 Jun 1;30(6):945-952. (PMID: 30860573) ESMO Open. 2021 Oct;6(5):100230. (PMID: 34479035) Mol Cancer Ther. 2016 Jun;15(6):1397-404. (PMID: 27207774) Clin Cancer Res. 2018 Apr 15;24(8):1872-1880. (PMID: 29330207) Clin Cancer Res. 2017 Aug 15;23(16):4716-4723. (PMID: 28420725) Clin Cancer Res. 2017 Sep 1;23(17):5101-5111. (PMID: 28539465) JCO Precis Oncol. 2020 Apr 2;4:. (PMID: 32923908) Ann Oncol. 2015 Aug;26(8):1715-22. (PMID: 25851626) Sci Transl Med. 2014 Feb 19;6(224):224ra24. (PMID: 24553385) Clin Cancer Res. 2019 Dec 1;25(23):7058-7067. (PMID: 31439586) Clin Cancer Res. 2020 Jun 15;26(12):2849-2858. (PMID: 32046999) JCO Precis Oncol. 2022 Feb;6:e2100197. (PMID: 35171660) Cancer Res. 2019 Mar 15;79(6):1214-1225. (PMID: 30541742) Ann Oncol. 2018 Jun 1;29(6):1445-1453. (PMID: 29635542) JCO Precis Oncol. 2021 Mar 19;5:. (PMID: 34095713) Curr Probl Cancer. 2017 May - Jun;41(3):212-221. (PMID: 28416241) Expert Rev Mol Diagn. 2015;15(12):1631-44. (PMID: 26559503) Cancer Discov. 2020 Dec;10(12):1842-1853. (PMID: 32816849) Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774) J Clin Oncol. 2013 Jan 1;31(1):17-22. (PMID: 23129736) Oncotarget. 2015 May 20;6(14):12809-21. (PMID: 25980577) Clin Cancer Res. 2016 Feb 1;22(3):567-74. (PMID: 26446943) Cancers (Basel). 2020 Apr 19;12(4):. (PMID: 32325878) J Thorac Oncol. 2021 Oct;16(10):1647-1662. (PMID: 34246791) Nat Rev Clin Oncol. 2013 Aug;10(8):472-84. (PMID: 23836314) Nat Rev Clin Oncol. 2020 Dec;17(12):757-770. (PMID: 32632268) Lancet. 2013 Jan 26;381(9863):303-12. (PMID: 23177514) Clin Cancer Res. 2020 Apr 15;26(8):1924-1931. (PMID: 31852833) Clin Cancer Res. 2018 Jan 1;24(1):181-188. (PMID: 29051321) |
| معلومات مُعتمدة: | P30 CA016672 United States CA NCI NIH HHS; R01 CA235620 United States CA NCI NIH HHS; UL1 TR000371 United States TR NCATS NIH HHS |
| المشرفين على المادة: | 0 (Biomarkers, Tumor) 0 (Circulating Tumor DNA) |
| تواريخ الأحداث: | Date Created: 20220714 Date Completed: 20220718 Latest Revision: 20230715 |
| رمز التحديث: | 20230715 |
| مُعرف محوري في PubMed: | PMC9307306 |
| DOI: | 10.1200/PO.21.00512 |
| PMID: | 35834760 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2473-4284 |
|---|---|
| DOI: | 10.1200/PO.21.00512 |